Company intelligence / Profile preview

LabGenomics

Seongnam-si, Gyeonggi-do, South Korealabgenomics.co.kr ↗

Ownership: Private
Employees: ~206
Development stage: Commercial

Overview

LabGenomics has commercialized several NGS-based cancer tests including BRCA1/BRCA2 testing, a comprehensive genetic cancer panel, and the OTD-Solid test. The company also developed a PCR-based SARS-CoV‑2 test kit with Emergency Use Authorization in 2020. It continues to expand its portfolio of advanced genetic tests for preventive and personalized medicine.

Therapeutic areas: OncologyInfectious Diseases
Modalities: NGS-based diagnosticsPCR-based diagnosticsDNA chip technology
Industry: Molecular Diagnostics

Partnerships

QDx Pathology acquisition

Beyond the preview

Go deeper on LabGenomics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LabGenomics.

Explore the full profile